Nixon Peabody Trust Co. Lowers Stock Position in IQVIA Holdings Inc. $IQV

Nixon Peabody Trust Co. cut its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 5.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 60,656 shares of the medical research company’s stock after selling 3,167 shares during the quarter. Nixon Peabody Trust Co.’s holdings in IQVIA were worth $9,559,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the company. Clal Insurance Enterprises Holdings Ltd grew its stake in IQVIA by 436.7% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 131 shares during the period. AllSquare Wealth Management LLC purchased a new stake in shares of IQVIA during the 1st quarter worth approximately $33,000. Trust Co. of Toledo NA OH bought a new stake in shares of IQVIA in the 2nd quarter worth approximately $39,000. J.Safra Asset Management Corp lifted its stake in IQVIA by 208.6% in the second quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 169 shares during the last quarter. Finally, NewSquare Capital LLC increased its position in IQVIA by 185.3% in the second quarter. NewSquare Capital LLC now owns 291 shares of the medical research company’s stock worth $46,000 after buying an additional 189 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on IQV. William Blair reiterated an “outperform” rating on shares of IQVIA in a research note on Wednesday, July 23rd. Barclays boosted their price target on shares of IQVIA from $185.00 to $200.00 and gave the company an “equal weight” rating in a research report on Thursday, October 2nd. Robert W. Baird set a $258.00 price objective on shares of IQVIA and gave the company an “outperform” rating in a research note on Wednesday, October 29th. Redburn Partners set a $214.00 target price on IQVIA in a research report on Wednesday, September 3rd. Finally, Stifel Nicolaus lifted their price target on IQVIA from $234.00 to $254.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and an average price target of $241.00.

IQVIA Price Performance

NYSE:IQV opened at $223.36 on Friday. The firm has a market capitalization of $38.04 billion, a price-to-earnings ratio of 30.64, a P/E/G ratio of 2.47 and a beta of 1.34. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. The stock has a fifty day moving average of $202.05 and a 200 day moving average of $178.04. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $228.12.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping the consensus estimate of $2.98 by $0.02. The company had revenue of $4.10 billion during the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.IQVIA’s revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Insider Transactions at IQVIA

In related news, insider Eric Sherbet sold 4,000 shares of the stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the transaction, the insider owned 27,108 shares of the company’s stock, valued at $5,955,627.60. This represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.60% of the company’s stock.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.